Valuation: Simulations Plus, Inc.

Market Cap 369M 323M 298M 275M 522M 35.18B 530M 3.56B 1.4B 17.33B 1.39B 1.35B 59.59B P/E 2026 *
44.8x
P/E 2027 * 41.9x
Enterprise Value 369M 323M 298M 275M 522M 35.18B 530M 3.56B 1.4B 17.33B 1.39B 1.35B 59.59B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 4.28x
Free-Float
82.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.55%
1 week-0.82%
Current month-0.38%
1 month+14.43%
3 months+39.88%
6 months-6.94%
Current year+0.05%
1 week 18.22
Extreme 18.22
18.45
1 month 16.14
Extreme 16.14
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.44
Extreme 7.44
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
06/07Sell

Executive/Senior Manager

-1,000 0.0050%
01/07Sell

Founder

-4,177 0.0207%
16/06Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-0.82%+3.81%-58.47% 369M
+0.22%-1.36%-32.50%-4.86% 30.88B
-6.34%-6.00%-37.97%+215.56% 14.32B
-0.77%-4.53%-20.85%+62.11% 5.64B
-3.61%-4.45% - - 2.3B
-1.47%+4.39%+50.89%-37.90% 2.04B
-8.87%-17.72% - - 1.84B
-0.98%-4.32%-30.06% - 1.09B
-6.61%-1.44%+46.34%+112.39% 948M
+0.60%+0.69%-33.62%+306.25% 832M
Average -2.84%-3.34%-6.74%+85.01% 6.03B
Weighted average by Cap. -2.04%-3.15%-28.08%+64.49%

Financials

2026 *2027 *
Net sales 81.87M 71.61M 66.05M 61M 116M 7.81B 118M 789M 310M 3.85B 307M 301M 13.22B 86.26M 75.45M 69.59M 64.27M 122M 8.23B 124M 831M 327M 4.05B 324M 317M 13.93B
Net income 9.23M 8.07M 7.45M 6.88M 13.05M 880M 13.27M 88.98M 34.94M 434M 34.66M 33.9M 1.49B 9.71M 8.49M 7.83M 7.23M 13.73M 926M 13.96M 93.6M 36.76M 456M 36.46M 35.66M 1.57B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
10/07/26 USD 18.24 -0.55% 423,570
09/07/26 USD 18.34 +0.38% 403,218
08/07/26 USD 18.27 -0.05% 397,537
07/07/26 USD 18.28 -0.44% 352,032
06/07/26 USD 18.36 -0.16% 340,704
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.24USD
Average target price
17.25USD
Spread / Average Target
-5.43%

Quarterly revenue - Rate of surprise